Free Cash Flow

The nation's largest EMS provider, GMR Solutions, saw its stock surge on its NYSE debut after a major IPO price cut to appease wary investors.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

The industrial giant affirms its quarterly payout, a sign of stability for investors as it navigates a costly green transition and recent regulatory hurdles.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

A new national survey reveals a crisis of trust in the American workplace, with widespread fear silencing employees and ethical pressures on the rise.

Amid a surging lithium market, Lithium Argentina posts stellar Q1 results, using its operational prowess to fund ambitious expansion projects in Argentina.

A massive acquisition and a surge in urea prices propelled Adecoagro to a record quarter, offsetting commodity slumps and redefining its future.

A new partnership tackles the rising financial threat of cognitive decline, helping Canadians protect their family, finances, and future from a growing crisis.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.

The former solar EV pioneer has completed its radical pivot, selling its solar business to management and betting its entire future on Bitcoin.

The federal tech firm posts a 23% revenue jump, eliminates debt, and builds a record backlog, signaling a new phase of strategic growth.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.

Scooter giant Lime files for a landmark IPO, but its S-1 reveals massive debt, setting up a crucial test for the future of urban transport.

Travel tech giant Amadeus navigates geopolitical turbulence with solid Q1 growth, while a major acquisition signals a bold future for frictionless travel.

The media giant posted strong Q3 results, driven by a bold strategy to monetize its content with AI partners while aggressively suing content scrapers.

The cloud company's results show modest growth, but a strategic pivot to shed a recent acquisition and focus on its 'Dash' AI tool is paying off.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

Semiconductor giant KLA announces a massive stock split and a 21% dividend hike, rewarding shareholders and making its stock more accessible to all.

The private energy giant posted $171M in free cash flow, cut debt, and earned a Fitch upgrade, signaling robust health amid market volatility.